Clinical Trial Update: A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers [Phase 2]

View source ↗

Summary

Phase 2 trial of carfilzomib plus dexamethasone in relapsed or refractory multiple myeloma was terminated at US community oncology centers; results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Amgen | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2021-01-08